This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
The approval for IM use was based on data from an open-label, crossover study that assessed the bioequivalence of single doses of 125mcg of Plegridy administered as an SC and IM injection. The Food ...
The US Food and Drug Administration (FDA) has approved intramuscular (IM) administration of peginterferon β-1a (Plegridy, Biogen) for patients with relapsing forms of multiple sclerosis (MS). "The new ...
Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. "The ...
Trogarzo (ibalizumab-uiyk) is currently approved in combination with other antiretroviral therapy for heavily treatment-experienced adults with multidrug resistant HIV-1 infection who are failing ...
Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...
The European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Plegridy ...